Evidence map›Paper›PMID 35141276›Full record

ArticleFrontiers in molecular biosciences2021

A Novel Fibrinolytic Protein From

Hai Liu, Jianqiong Yang, Yamei Li, Yunnan Ma, Wenjie Wang, Wanling Zhong, Pengyue Li, Shouying Du

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hai LiuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Jianqiong YangThe First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Yamei LiCollege of Pharmacy, Gannan Medical University, Ganzhou, China.
Yunnan MaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Wenjie WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Wanling ZhongSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Pengyue LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Shouying DuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Beijing University of Chinese Medicine · CNGannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic diseases have been considered major causes of death around the world. Treatments with thrombolytic drugs, such as recombinant tissue-plasminogen activator, urokinase, and streptokinase, are reported to have a life-threatening bleeding tendency. On the contrary, lumbrokinase, identified from

Indexed as

antithrombotic evaluationde novo sequencingfibrinolytic proteinmolecular dockingPheretima vulgarispurification

Identifiers

PMID35141276
PMCPMC8819685
OpenAlexW4207054563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.